港股详情

本页面由Tiger Fintech (Singapore) Pte. Ltd.提供服务

生物医药B类股

619.832

-11.249-1.78%

涨家数：6

跌家数：25

平家数：3

市盈率：- -

高：633.508

开：631.081

低：614.387

收：631.081

成交量：8,515.90万

成交额：17.99亿

市值：3,809.30亿

流通市值：3,408.71亿

数据加载中...

总览新闻资讯

礼邦医药冲击港股IPO，专注于肾脏病领域，存在潜在市场重叠风险

创新药板块调整后何去何从？泓德基金操昭煦：政策与出海双轮驱动，创新药板块估值具备吸引力

腾盛博药-B11月17日遭主力抛售130.1万元

A股收评：指数集体下跌！军工、福建板块强势，贵金属、医药板块走低

港股创新药概念股持续下跌联邦制药跌超8%

每日经济新闻

业绩不佳但名字“讨彩”？这家公司股价6连板

康方生物针对Aβ和Bbb表达受体的双特异性抗体获得中国阿尔茨海默病临床试验批准

中国抗体-B盘中异动大幅跳水5.00%报1.710港元

“十五五”规划建议出炉，这些医药细分领域机遇凸显！

和誉-B(02256)：和誉医药于CTOS 2025年会展示匹米替尼临床III期 MANEUVER研究长期疗效和安全性数据

中信建投：预计26年医疗器械公司将迎业绩拐点板块估值正在被重估

医药榜成都医药企业占据两席商业航天榜上榜企业正在成都造火箭

农银汇理基金经理梦圆：把握中国创新药成长机遇

产业化阶段奖励1000万元重庆真金白银催生创新药

4000点拉锯战，制药板块缘何低调逆袭？基金经理火线解读！

投资科迈生物，华兰股份押宝AI创新药

众生药业(002317.SZ)：创新药研发项目临床试验进度、审评和审批结果具有不确定性

网上药店破700亿，51个品牌销售过亿

米内零售观察

看，这家生物医药“梦工厂”的“药”强之路

股价上涨超140%，ADC领域的“隐形赢家”

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/hans/stock/BK1574/news"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"BK1574","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK1574\",,,,,undefined,":{"symbol":"BK1574","market":"HK","secType":"PLATE","nameCN":"生物医药B类股","latestPrice":619.83203,"timestamp":1763366893506,"preClose":631.0813,"halted":0,"volume":85158970,"delay":0,"changeRate":-0.017825,"floatShares":0,"shares":0,"eps":0,"marketStatus":"已收盘","change":-11.249268,"latestTime":"11-17 16:00:00","open":631.0813,"high":633.5082,"low":614.387,"amount":1799340647,"amplitude":0.030299,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1763429400000},"marketStatusCode":0,"adr":0,"adjPreClose":0,"openAndCloseTimeList":[[1763343000000,1763352000000],[1763355600000,1763366400000]],"pbRate":5.386036,"peRate":-44.459922,"turnoverRate":0.003108,"increases":6,"decrements":26,"flats":1,"marketCap":380930473472,"floatMarketCap":340871157584},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK1574\",,,,,undefined,":{"symbol":"BK1574","high":633.5082,"amplitude":0.030299,"preClose":631.0813,"low":614.387,"pbRate":"5.386036","latestPrice":619.83203,"volume":85158970,"delay":0,"open":631.0813,"prevYearClose":331.1933,"prevWeekClose":631.081,"prevMonthClose":618.706,"prevQuarterClose":752.859,"fiveDayClose":602.134,"twentyDayClose":646.836,"sixtyDayClose":790.38,"secType":"PLATE","market":"HK","turnoverRate":0.003108,"peRate":-44.459922,"marketCap":380930473472,"floatMarketCap":340871157584,"timestamp":1763366893506,"nameCN":"生物医药B类股"},"@#url:\"https://hq.skytigris.cn/api/global/plate/up_down\",method:\"POST\",data:#delay:false,bkCodes:@\"BK1574\",,,,undefined,":{"bkCode":"BK1574","up":6,"down":25,"flat":3},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"BK1574\",pageSize:20,pageCount:1,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2584864699","title":"礼邦医药冲击港股IPO，专注于肾脏病领域，存在潜在市场重叠风险","url":"https://stock-news.laohu8.com/highlight/detail?id=2584864699","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584864699?lang=zh_cn&edition=fundamental","pubTime":"2025-11-17 17:30","pubTimestamp":1763371806,"startTime":"0","endTime":"0","summary":"两年半累计亏损9.1亿元","market":"us","thumbnail":"https://img2.gelonghui.com/16c8d-f2669b06-8436-4774-bfc1-8e7cafddcf5f.jpg?guru_height=891&guru_width=1364&guru_size=109981","type":0,"news_type":0,"thumbnails":["https://img2.gelonghui.com/16c8d-f2669b06-8436-4774-bfc1-8e7cafddcf5f.jpg?guru_height=891&guru_width=1364&guru_size=109981"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/p/3211874","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"gelonghui_highlight","symbols":["BK1161","09939","BK1574","BK1515"],"gpt_icon":0},{"id":"2584643503","title":"创新药板块调整后何去何从？ 泓德基金操昭煦：政策与出海双轮驱动，创新药板块估值具备吸引力","url":"https://stock-news.laohu8.com/highlight/detail?id=2584643503","media":"新浪基金","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584643503?lang=zh_cn&edition=fundamental","pubTime":"2025-11-17 16:38","pubTimestamp":1763368680,"startTime":"0","endTime":"0","summary":"今年5月以来，创新药板块在政策与产业的双重驱动下持续受到市场关注。10月30日，2025年国家医保药品目录谈判的完成及首版商保创新药目录的引入，为高价创新药开辟了新的支付路径，奠定了行业重要的政策基础。　　十月创新药板块迎来年内首次中期回调，泓德基金基金经理操昭煦表示，这主要由于前期涨幅过快，部分活跃资金转向其他板块所致。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/money/fund/jjh/2025-11-17/doc-infxsxxz5534374.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["159992","BK1574","06978","BK1161"],"gpt_icon":0},{"id":"2584564333","title":"腾盛博药-B11月17日遭主力抛售130.1万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2584564333","media":"市场透视","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584564333?lang=zh_cn&edition=fundamental","pubTime":"2025-11-17 16:15","pubTimestamp":1763367310,"startTime":"0","endTime":"0","summary":"11月17日, 腾盛博药-B股价跌3.30%，报收1.76元，成交金额743.0万元，换手率0.58%，振幅4.95%，量比2.10。腾盛博药-B今日主力资金净流出130.1万元，上一交易日主力净流出159.7万元。该股近5个交易日下跌3.30%，主力资金累计净流出354.6万元，其中1个交易日为股价上涨时净流出；近20日主力资金累计净流出1059.2万元，其中净流出天数为11日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251117161535a6fed993&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251117161535a6fed993&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["02137","BK1574","BK1587","BK1161"],"gpt_icon":0},{"id":"2584338610","title":"A股收评：指数集体下跌！军工、福建板块强势，贵金属、医药板块走低","url":"https://stock-news.laohu8.com/highlight/detail?id=2584338610","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584338610?lang=zh_cn&edition=fundamental","pubTime":"2025-11-17 15:40","pubTimestamp":1763365233,"startTime":"0","endTime":"0","summary":"沪深两市成交额1.91万亿","market":"fut","thumbnail":"https://img3.gelonghui.com/a48cd-6da2875c-c1af-4256-a34f-0987cf96fa90.png?guru_height=540&guru_width=375","type":0,"news_type":0,"thumbnails":["https://img3.gelonghui.com/a48cd-6da2875c-c1af-4256-a34f-0987cf96fa90.png?guru_height=540&guru_width=375"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/p/3211089","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"gelonghui_highlight","symbols":["LU0072913022.USD","BK1161","BK0188","BK0278","LU1226287529.USD","LU0067412154.USD","LU1807302812.USD","BK1515","BK0187","BK0183","LU0880133367.SGD","09939","BK1574","LU1655091616.SGD","BK0028","BK0012","LU1781817850.SGD","000001","IE00B0JY6N72.USD","LU1580142542.USD","LU1993786604.SGD","LU0501845795.SGD","BK0201"],"gpt_icon":0},{"id":"2584459611","title":"港股创新药概念股持续下跌 联邦制药跌超8%","url":"https://stock-news.laohu8.com/highlight/detail?id=2584459611","media":"每日经济新闻","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584459611?lang=zh_cn&edition=fundamental","pubTime":"2025-11-17 14:05","pubTimestamp":1763359521,"startTime":"0","endTime":"0","summary":"每经AI快讯，港股创新药概念股持续下跌，联邦制药跌超8%，晶泰控股、巨子生物、三生制药、中国生物制药等跟跌。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202511173566172317.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202511173566172317.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK1574","BK1191","BK1161","06978","03933"],"gpt_icon":0},{"id":"2584761624","title":"业绩不佳但名字“讨彩”？这家公司股价6连板","url":"https://stock-news.laohu8.com/highlight/detail?id=2584761624","media":"证券日报","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584761624?lang=zh_cn&edition=fundamental","pubTime":"2025-11-17 12:53","pubTimestamp":1763355180,"startTime":"0","endTime":"0","summary":"　　在医药板块整体表现平平的背景下，哈药集团人民同泰医药股份有限公司股价却持续飙升。　　Wind数据显示，截至11月17日午间收盘，人民同泰已连续6个交易日涨停，公司股价从11月10日的9.20元/股一路飙升至11月17日的16.64元/股，累计涨幅高达77.21%，总市值达到96亿元。2025年前三季度，人民同泰实现营业收入78.46亿元，同比增长2.19%；归属于上市公司股东的净利润1.12亿元，同比下降45.69%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/s/2025-11-17/doc-infxstsk3761786.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK1515","600829","09939","BK1161","BK1574","BK0250"],"gpt_icon":0},{"id":"1186927647","title":"康方生物针对Aβ和Bbb表达受体的双特异性抗体获得中国阿尔茨海默病临床试验批准","url":"https://stock-news.laohu8.com/highlight/detail?id=1186927647","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1186927647?lang=zh_cn&edition=fundamental","pubTime":"2025-11-17 10:30","pubTimestamp":1763346610,"startTime":"0","endTime":"0","summary":"康方生物针对Aβ和Bbb表达受体的双特异性抗体获得中国阿尔茨海默病临床试验批准","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0634319403.HKD","LU0348767384.USD","IE00B543WZ88.USD","LU0417516738.SGD","LU1961090484.USD","LU0348784397.USD","LU2778985437.USD","LU0561508036.HKD","09926","LU0348783233.USD","LU2399975544.HKD","LU0417516571.SGD","LU0417516902.SGD","IE00B5MMRT66.SGD","LU0348825331.USD","LU0348827113.USD","IE00BPRC5H50.USD","LU1794554557.SGD","LU2488822045.USD","BK1161","LU0348766576.USD","LU0540923850.HKD","LU2476274720.SGD","BK1574","LU1720050803.USD","LU2476274308.USD","LU0348735423.USD"],"gpt_icon":0},{"id":"2584998616","title":"中国抗体-B盘中异动 大幅跳水5.00%报1.710港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2584998616","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584998616?lang=zh_cn&edition=fundamental","pubTime":"2025-11-17 10:04","pubTimestamp":1763345066,"startTime":"0","endTime":"0","summary":"2025年11月17日早盘10时04分，中国抗体-B股票出现异动，股价急速下挫5.00%。截至发稿，该股报1.710港元/股，成交量111.51万股，换手率0.08%，振幅4.44%。资金方面，该股资金流入17.0391万港元，流出176.115万港元。中国抗体-B股票所在的生物技术行业中，整体跌幅为2.36%。其相关个股中，来凯医药-B、中生北控生物科技、东曜药业-B涨幅较大，振幅较大的相关个股有派格生物医药-B、MIRXES-B、来凯医药-B，振幅分别为27.98%、11.60%、10.21%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251117100426a4a66bde&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251117100426a4a66bde&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["03681","BK1161","BK1574"],"gpt_icon":0},{"id":"2584764358","title":"“十五五”规划建议出炉，这些医药细分领域机遇凸显！","url":"https://stock-news.laohu8.com/highlight/detail?id=2584764358","media":"制药网","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584764358?lang=zh_cn&edition=fundamental","pubTime":"2025-11-17 09:35","pubTimestamp":1763343311,"startTime":"0","endTime":"0","summary":"随着“十五五”规划建议出炉，为中国医药行业锚定了“创新驱动、自主可控、普惠可及”的发展航向。创新药作为医药产业的核心引擎，在“十五五”规划“支持创新药发展”的政策导向下迎来黄金发展期。“十五五”规划明确支持医疗器械发展，医疗设备“以旧换新”政策与医疗卫生强基工程的推进，直接拉动基层医疗设备更新需求，AI影像、心血管介入器械等细分领域国产化率已突破50%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202511170936269508c76b&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202511170936269508c76b&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1588","LU1770034418.SGD","BK1500","LU0588546209.SGD","LU1303224171.USD","LU0307460666.USD","LU1719994722.HKD","BK1574","BK1583","BK1515","06160","09939","LU1969619763.USD","LU1251922891.USD","LU2328871848.SGD","BK1161"],"gpt_icon":0},{"id":"2584691270","title":"和誉-B(02256)：和誉医药于CTOS 2025年会展示匹米替尼临床III期 MANEUVER研究长期疗效和安全性数据","url":"https://stock-news.laohu8.com/highlight/detail?id=2584691270","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584691270?lang=zh_cn&edition=fundamental","pubTime":"2025-11-17 08:02","pubTimestamp":1763337752,"startTime":"0","endTime":"0","summary":"智通财经APP讯，和誉-B(02256)发布公告，本公司的附属公司上海和誉生物医药科技有限公司(和誉医药)宣布，其在结缔组织肿瘤学会(CTOS)2025年会上以壁报形式展示了匹米替尼(pimicotinib/ABSK021)治疗腱鞘巨细胞瘤(TGCT)患者的全球III期MANEUVER研究的长期疗效、安全性及患者报告结果数据。该长期分析显示，持续接受匹米替尼治疗可为TGCT患者在肿瘤缓解方面带来疗效持续提升与患者报告结果(包括疼痛与功能)的进一步改善，同时维持可接受的安全性，强化了匹米替尼在适合患者中的长期应用潜力。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1369759.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4134","LU2476274308.USD","III","BK1515","02256","LU2476274720.SGD","CTOS","BK1161","IE00B543WZ88.USD","IE00BPRC5H50.USD","LU2778985437.USD","BK1574","LU2488822045.USD","BK4104","IE00B5MMRT66.SGD","159938","09939"],"gpt_icon":0},{"id":"2584691325","title":"中信建投：预计26年医疗器械公司将迎业绩拐点 板块估值正在被重估","url":"https://stock-news.laohu8.com/highlight/detail?id=2584691325","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584691325?lang=zh_cn&edition=fundamental","pubTime":"2025-11-17 07:34","pubTimestamp":1763336040,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，中信建投证券发布研报称，短期来看，随着政策缓和、集采出清、新产品新业务拓展和出海布局，预计26年多家医疗器械龙头公司迎来业绩拐点，建议把握业绩估值修复投资机会，以及脑机接口、AI医疗等医疗新科技方向投资机会。医疗器械板块的长期投资机会来自创新、出海和并购整合，板块的创新性和国际化能力逐步得到认可、估值正在被重估。IVD：2026年板块业绩仍受多重政策影响，但相比25年有望改善。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1369753.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["601066","09997","BK1222","BK1100","BK1583","BK1574","09996","BK0276","159883"],"gpt_icon":0},{"id":"2584974106","title":"医药榜成都医药企业占据两席 商业航天榜上榜企业正在成都造火箭","url":"https://stock-news.laohu8.com/highlight/detail?id=2584974106","media":"成都日报","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584974106?lang=zh_cn&edition=fundamental","pubTime":"2025-11-17 03:14","pubTimestamp":1763320440,"startTime":"0","endTime":"0","summary":"转自：成都日报锦观福布斯中国创新力企业50强榜出炉医药榜成都医药企业占据两席 商业航天榜上榜企业正在成都造火箭星际荣耀可重复使用液体运载火箭生产总部基地效果图。榜单显示，成都生物医药行业表现不俗，在入选的全国8家医药企业中，成都占据两席，分别是百利天恒和科伦博泰生物。值得关注的还有，在商业航天领域创新力企业榜中，星际荣耀上榜，为商业航天领域两家上榜企业之一。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025111703162295084ef3&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025111703162295084ef3&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["06990","BK1574","BK1515","09939","LU0196878994.USD","BK1161"],"gpt_icon":0},{"id":"2584696032","title":"农银汇理基金经理梦圆：把握中国创新药成长机遇","url":"https://stock-news.laohu8.com/highlight/detail?id=2584696032","media":"东方财富","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584696032?lang=zh_cn&edition=fundamental","pubTime":"2025-11-17 02:16","pubTimestamp":1763316975,"startTime":"0","endTime":"0","summary":"要理解中国创新药面临的成长机遇，首先要回到本轮创新药板块上涨的核心逻辑——年初以来中国创新药的加速出海，是这轮创新药板块上涨的力量。中国创新药对外授权交易数量占比显著提升，在首付款超0.5亿美元的跨国药企创新药交易中，从中国企业引入的数量占比在2024年达到27%，2025年前三季度已升至38%。这推动了中国创新药企业估值持续攀升。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251117021620a6fd92df&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251117021620a6fd92df&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1588","02359","06978","LU0307460666.USD","BK1161","LU1770034418.SGD","LU2328871848.SGD","LU1303224171.USD","LU1719994722.HKD","BK1583","LU0588546209.SGD","LU1251922891.USD","LU1969619763.USD","BK1574","BK1500","06160"],"gpt_icon":0},{"id":"2584660859","title":"产业化阶段奖励1000万元 重庆真金白银催生创新药","url":"https://stock-news.laohu8.com/highlight/detail?id=2584660859","media":"重庆晨报","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584660859?lang=zh_cn&edition=fundamental","pubTime":"2025-11-17 00:18","pubTimestamp":1763309880,"startTime":"0","endTime":"0","summary":"市经济信息委副主任罗莉在会上宣布，重庆将实施全链条资金支持策略，对实现产业化的每个创新药给予1000万元奖励，力争到2027年全市创新药总数达到10个。在产业化阶段，对获批上市的创新药每个奖励1000万元，改良型新药、生物类似药每个奖励500万元，中药经典名方产品每个奖励100万元，以实实在在的资金支持创新成果转化。在市场开拓阶段，对创新药成果海外权益许可交易，按首付款的3%给予最高500万元奖励，助力本土创新药走向全球市场。","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/jjxw/2025-11-17/doc-infxrmwu7169765.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["159992","QImain","06978","BK1574","SImain","BK1161"],"gpt_icon":0},{"id":"2583664516","title":"4000点拉锯战，制药板块缘何低调逆袭？基金经理火线解读！","url":"https://stock-news.laohu8.com/highlight/detail?id=2583664516","media":"新浪基金","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583664516?lang=zh_cn&edition=fundamental","pubTime":"2025-11-16 19:52","pubTimestamp":1763293920,"startTime":"0","endTime":"0","summary":"11月14日，大市深度调整，沪指跌0.97%报收3990.39点，创指跌2.82%尽吐上日涨幅。震荡之际，制药板块彰显防御力！全市场唯一跟踪制药指数的药ETF盘中逆市飘红，一度冲高1%，场内最终微跌0.18%，显著跑赢市场。　　药ETF覆盖50大龙头药企，重仓创新药，兼顾中药。恒瑞医药、百济神州-U、片仔癀等龙头股下跌为主要拖累。　　本周，A股制药板块以反弹行情为主，药ETF单周累涨3.33%，较大市跑出显著超额收益，沪指周跌0.18%，创指周跌3.01%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/money/fund/etf/2025-11-16/doc-infxqzie4577740.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK1574","01477","BK1191"],"gpt_icon":0},{"id":"2583661745","title":"投资科迈生物，华兰股份押宝AI创新药","url":"https://stock-news.laohu8.com/highlight/detail?id=2583661745","media":"北京商报","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583661745?lang=zh_cn&edition=fundamental","pubTime":"2025-11-16 18:15","pubTimestamp":1763288100,"startTime":"0","endTime":"0","summary":"　　具体来看，灵擎数智与深圳晶泰拟共同向科迈生物进行增资入股。华兰股份表示，未来，公司将深化布局AI创新药研发领域，积极引入国内外顶尖的行业专家，以多元化的方式构建业务团队，提升技术服务能力。此次投资有利于华兰股份快速切入高附加值的AI创新药赛道，培育第二增长曲线，同时反哺自身核心包装业务，形成业务协同效应。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/stock/relnews/cn/2025-11-16/doc-infxqzhx6367458.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/relnews/cn/2025-11-16/doc-infxqzhx6367458.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK1161","06978","BK0239","301093","159992","BK1574"],"gpt_icon":0},{"id":"2583666072","title":"众生药业(002317.SZ)：创新药研发项目临床试验进度、审评和审批结果具有不确定性","url":"https://stock-news.laohu8.com/highlight/detail?id=2583666072","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583666072?lang=zh_cn&edition=fundamental","pubTime":"2025-11-16 16:45","pubTimestamp":1763282731,"startTime":"0","endTime":"0","summary":"创新药研发项目的临床试验进度、审评和审批的结果以及未来产品市场竞争格局都具有一定的不确定性。药品能否获批上市以及获批上市的时间、上市后的生产和销售情况存在不确定性。用于治疗成人单纯性甲型流感的小分子创新药昂拉地韦片已获得国家药品监督管理局批准上市，是全球首款流感RNA聚合酶PB2蛋白抑制剂。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1369698.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0077","002317","06978","BK1574","BK1161","BK0188","159992","BK0239"],"gpt_icon":0},{"id":"2583661268","title":"网上药店破700亿，51个品牌销售过亿","url":"https://stock-news.laohu8.com/highlight/detail?id=2583661268","media":"米内零售观察","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583661268?lang=zh_cn&edition=fundamental","pubTime":"2025-11-16 14:00","pubTimestamp":1763272845,"startTime":"0","endTime":"0","summary":"米内网数据显示，2024年网上药店药品的销售规模已突破700亿元，2025上半年增长了20.36%。51个药品卖过亿！整体来看，51个销售额过亿的品牌中有32个品牌有正增长，最高增幅是2267.10%；19个品牌负增长，降幅最高为55.44%，诺和诺德的司美格鲁肽注射液、乐福思的他达拉非片等7个品牌降幅超过20%，需加倍努力。国药集团手握2个过亿品牌，均为化学药，合揽超过5亿元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251116140323a6fc9c0d&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251116140323a6fc9c0d&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1191","01477","BK1606","BK1574","03320","06887","BK1197","BK1515","BK1521","00874"],"gpt_icon":0},{"id":"2583662616","title":"看，这家生物医药“梦工厂”的“药”强之路","url":"https://stock-news.laohu8.com/highlight/detail?id=2583662616","media":"南京日报","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583662616?lang=zh_cn&edition=fundamental","pubTime":"2025-11-16 08:00","pubTimestamp":1763251200,"startTime":"0","endTime":"0","summary":"让老百姓用得上、用得起创新药看，这家生物医药“梦工厂”的“药”强之路□ 南京日报/紫金山新闻记者 张安琪蹲点主题：生物制造从技术突破到产业升级蹲点点位：正大天晴药业集团生病时，一粒药丸、一支药剂，能守护健康，甚至能为生命续航。一款生物药的“成长之路”从冷冻罐中的细胞种子开始。陆建胜表示，这条万升产线自建成以来，已生产百余批次生物药，零安全事故记录。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251116083808a4a45ece&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251116083808a4a45ece&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["HK0000165453.HKD","IE00BZ08YS42.EUR","BK1521","IE00BZ08YT58.USD","BK1589","BK1574","01177","BK1515","BK1191","BK1161","06978","IE00BZ08YR35.GBP"],"gpt_icon":0},{"id":"2583669633","title":"股价上涨超140%，ADC领域的“隐形赢家”","url":"https://stock-news.laohu8.com/highlight/detail?id=2583669633","media":"药渡","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583669633?lang=zh_cn&edition=fundamental","pubTime":"2025-11-16 07:30","pubTimestamp":1763249459,"startTime":"0","endTime":"0","summary":"2025年10月，中国创新药再次被ADC领域的巨额BD交易彻底点燃。在这场ADC狂欢中，最引人注目的除了手握重磅管线的创新药企，还有ADC领域的“卖铲人”——皓元医药。今年以来，截至10月31日，皓元医药的股价从35.47元/股，一路上涨至最高88.38元/股，涨幅超过140%，成为资本市场的“隐形赢家”。3ADC黄金时代皓元医药股价大幅上涨，与近些年ADC药物市场的爆发密切相关。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251116090353a6fc3962&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251116090353a6fc3962&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1589","03692","09995","BK1574","BK1191","06978","02615","BK1161","BK1583","LU1969619763.USD","01801","LU2328871848.SGD"],"gpt_icon":0}],"pageSize":20,"totalPage":31,"pageCount":1,"totalSize":608,"code":"91000000","status":"200"}]}}